Nirmatrelvir/ritonavir Use and Hospitalizations or Death in Previously Uninfected Non-hospitalized High-risk Population with COVID-19: A matched cohort study.
Adeel Ajwad ButtPeng YanObaid S ShaikhVictor B TalisaSaad B OmerFlorian B MayrPublished in: The Journal of infectious diseases (2023)
NMV/r is associated with a significant reduction in 30-day hospitalization or death among previously uninfected, non-hospitalized individuals.